Cost-effectiveness analysis of HRD testing for patients with advanced ovarian cancer in Italy: an update
Abstract
IntroductionOvarian cancer (OC) is the eighth most common cancer among women, with homologous recombination deficiency (HRD) present in about 50% of cases. In this subgroup, poly (ADP-ribose) polymerase (PARP) inhibitors show greater therapeutic benefit. This study aimed to update a cost-effectiveness analysis comparing upfront HRD testing with BRCA-only testing (BReast CAncer gene), which identifies mutations in roughly 25% of patients, to inform and optimize treatment strategies in Italy.MethodsA previously developed cost-effectiveness model was updated to incorporate new clinical evidence and cost data for PARP inhibitors (niraparib, rucaparib). The model projected costs and outcomes - life-years (LYs) and quality-adjusted life-years (QALYs) - over a lifetime horizon, comparing immediate HRD testing with BRCA testing alone or with sequential HRD testing after a negative BRCA result. Analyses were conducted from the Italian National Healthcare Service (NHS) perspective. Deterministic and probabilistic sensitivity analyses, together with scenario and threshold analyses, assessed the robustness of model results.ResultsUpfront HRD testing remained cost-effective versus BRCA-only testing, with an incremental cost-utility ratio of 22,476€/QALY, and was cost-saving compared with sequential testing. Probabilistic sensitivity analysis showed that HRD testing was cost-effective in 99.3% of simulations considering a 50,000€/QALY willingness-to-pay threshold. Findings were robust across most scenarios, however cost-effectiveness was reversed with a 10-year time horizon, an HRD-positive/BRCA-negative prevalence in the range 3.95%-4.99%, or substantial acquisition cost increases for olaparib or rucaparib.DiscussionAlthough identifying genetic alterations in advanced OC incurs significant costs, upfront HRD testing is a cost-effective strategy compared with BRCA-only testing when considering all currently available treatment options. It enables more efficient allocation of healthcare resources while improving life expectancy and quality of life for women with advanced ovarian cancer.
Related
- Effectiveness of a Molecular Tumor Board in Making Personalized Treatment Recommendations for Patients with Advanced Cancer
- Can Routine Preoperative Endoscopy and Colonoscopy Be Meaningful for the Surgery and Postoperative Course of Patients with Advanced Ovarian Cancer? A Single-Centre Retrospective Cohort Study.
- The Effectiveness of Web-based Self-Compassion Training on Caregiving Burden and Quality of Life of Family Caregivers of Patients with Advanced Cancer: A Study Protocol for a Single-blind, Two-arm Parallel Randomized Controlled Trial
- Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer
- Molecular Testing Among Patients With Advanced Non–Small Cell Lung Cancer in the Rural US
BibTeX
@article{rognoni2026costeffectiveness,
title = {{Cost-effectiveness analysis of HRD testing for patients with advanced ovarian cancer in Italy: an update}},
author = {Carla Rognoni and Domenica Lorusso and Francesco Costa and Patrizio Armeni},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1857834},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1857834},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cost-effectiveness analysis of HRD testing for patients with advanced ovarian cancer in Italy: an update
AU - Carla Rognoni
AU - Domenica Lorusso
AU - Francesco Costa
AU - Patrizio Armeni
PY - 2026
DA - 2026/11/02
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1857834
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1857834
AB - IntroductionOvarian cancer (OC) is the eighth most common cancer among women, with homologous recombination deficiency (HRD) present in about 50% of cases. In this subgroup, poly (ADP-ribose) polymerase (PARP) inhibitors show greater therapeutic benefit. This study aimed to update a cost-effectiveness analysis comparing upfront HRD testing with BRCA-only testing (BReast CAncer gene), which identifies mutations in roughly 25% of patients, to inform and optimize treatment strategies in Italy.MethodsA previously developed cost-effectiveness model was updated to incorporate new clinical evidence and cost data for PARP inhibitors (niraparib, rucaparib). The model projected costs and outcomes - life-years (LYs) and quality-adjusted life-years (QALYs) - over a lifetime horizon, comparing immediate HRD testing with BRCA testing alone or with sequential HRD testing after a negative BRCA result. Analyses were conducted from the Italian National Healthcare Service (NHS) perspective. Deterministic and probabilistic sensitivity analyses, together with scenario and threshold analyses, assessed the robustness of model results.ResultsUpfront HRD testing remained cost-effective versus BRCA-only testing, with an incremental cost-utility ratio of 22,476€/QALY, and was cost-saving compared with sequential testing. Probabilistic sensitivity analysis showed that HRD testing was cost-effective in 99.3% of simulations considering a 50,000€/QALY willingness-to-pay threshold. Findings were robust across most scenarios, however cost-effectiveness was reversed with a 10-year time horizon, an HRD-positive/BRCA-negative prevalence in the range 3.95%-4.99%, or substantial acquisition cost increases for olaparib or rucaparib.DiscussionAlthough identifying genetic alterations in advanced OC incurs significant costs, upfront HRD testing is a cost-effective strategy compared with BRCA-only testing when considering all currently available treatment options. It enables more efficient allocation of healthcare resources while improving life expectancy and quality of life for women with advanced ovarian cancer.
SN - 2234-943X
ER -